{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001831","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.833903+00:00","generated_at":"2026-05-24T01:43:24.982989+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025","bullets":["Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.","Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.","First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.","Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.","Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001831","json":"https://secwatch.observer/filing/0001641172-25-001831.json","markdown":"https://secwatch.observer/filing/0001641172-25-001831.md","text":"https://secwatch.observer/filing/0001641172-25-001831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/0001641172-25-001831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:43:24.982989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}